Exchange: NASDAQ·Updated 07:30 PM EST
KZIA logo

KZIA Kazia Therapeutics

$5.05
$0.45
(8.38%)
Today
Closed $4.92
$0.13
(2.64%)
After Hours
Mkt Cap$62.45M
Vol732,078.00

About KZIA

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
48

Neutral Sentiment

How do you feel about KZIA?

Rinnekin
$KZIA SABCS abstract titles: Abstract P4-9-18 “Paxalisib uniquely induces durable tumour and immune reprogramming across breast cancer subtypes, challenging the paradigm that dual PI3K/mTOR inhibitors are biologically equivalent.” * Presenting investigator: Sudha Rao * Institution: QIMR Berghofer Medical Research Institute, Herston, Australia * Session: Poster Session 4, December 10, 2026 * Official source: SABCS Poster Session 4⁠ Abstract P4-10-26 “Suppression of Local and Metastatic Recurrence by Adjuvant PI3K/mTOR Inhibition Through Durable Immune Epigenetic Rewiring Following Neoadjuvant Chemo-Immunotherapy in Stage III Triple-Negative Breast Cancer.” * Presenting investigator: Sudha Rao * Institution: QIMR Berghofer Medical Research Institute * Official source: SABCS Poster Session 4⁠
13
Rinnekin
$KZIA Well, that’s a ”tad” overdone … If you liked it at $12+, you gotta love it at less than $5. For those who need their investment in the coming weeks, it’s truly painful. For everyone else, just sit tight. Trials are funded, no adverse clinical data released. The investment story is intact.
8
10baggerPete
$KZIA folks it's almost 2027 why are folks posting negative news from 2023? It like being parked outside your ex's house to warn off new suiters! It just doesn't reflect well on your mental state. Grief Therapy might be right for some of you!
7
StantheMan32
$KZIA Now we rebuild. I assume Rene will post the "text based" SABC abstracts on Monday night. Buying Kazia below cash may prove to be one of the greatest buys in biotech history. An extended runway with 7 or 8 shots on goal and you get it all for free under $5. INSANE opportunity
4
futureexmillionare
$KZIA hello November .. no updates with FDA …they are working hard .. and here everyone wanted to be at $20-$30.. here’s again another chances to accumulate..
6
StantheMan32
$KZIA Dr Rinnekin's SABC Nov.23rd date is rapidly approaching. Can you say Monday night? Full abstract texts will be released online
5
LabMan
$KZIA Virtually at cash backing, for the ONLY safe, brain penetrate PI3K mTOR, multi isoform drug. The stupidity of this situation has arrived specifically because of well documented company performance. Distain is my view of the company. But only one poster here has declared active push back against this company incompentence. Shareholder activism is broadly part of equity markets- but only this poster, tries to do anything about it. The formal Parkinson's Disease collarbration and subsequent breach of legal obligation - via zero updated company disclosure, is a no go zone for other investors ( as only this poster has ever ever mentioned PD here). Do nothing and you are getting what you deserve. Much precentant exists for replacement of the CEO, in this overall circumstance. But despite the cash backing float size, some still strongly supporting the company. I stand by - pAX as one of the most valuable drugs in development. Again here from the Swiss medical publication group.
5
ItsAllAboutBeingFirst
Im back in $kzia $airs $open and $crml.... Bunch of news and catalysts at on sale prices... keep adding to em everyday
5
futureexmillionare
$KZIA Last year, KZIA filed its annual financial results on Friday, November 7, 2025 so probably next week we should have one for this year . Still no FDA news .. it’s been long time…the latest public data shows 42 institutional holders and 8 analysts covering KZIa. ..
5
StantheMan32
$KZIA Hopefully some more text based info here next week. Not data , but perhaps a morsel of more information https://stocktwits.com/Rinnekin/message/667833454
4
JeffHSquared
$KZIA Coming up on an all-time low. Wow. And the company is so much better positioned than in the past. Crazy.
4
futureexmillionare
$KZIA maybe there was no meeting ? Everyone is waiting and we have not received any updates. End of the year is ticking and we are back at $5 . I wonder why ? Those investors that bought probably already sold their shares .
2
ocellated
$KZIA So I think Kazia has complete autonomy of the tnbc trial data being conducted by QIMR Berghoffer and since Kazia is the sponsor they could release any data any time they want I guess. I'm not aware of any restrictions. Maybe they are bound to the SABCC people not to release any of the same data prior to the abstract release. But could they be negotiating a deal right now with big(ger) pharma if the next data set is already known to be good?
2
10baggerPete
$KZIA That's some nasty price action and we are not done with tax loss selling yet. oof!
2
LabMan
$KZIA The Dana-Farber Cancer Phase II trial evaluating paxalisib in combination with trastuzumab for HER2-positive breast cancer brain metastases - initiated in late 2018 has just reported failure in searches that are prominently Google available. Maybe this has contributed somewhat, to heavy selling. Nothing from the company,?? on this very high profile (at the time) study-despite a no of positives. CNS was primary purpose, but still OS of 16.5 in 17 heavily metastatic partients, was strong. Half of patients achieved stable disease, in patients on average, treated previously with 5 approved drugs. Subsequently it is known trastuzumab - approved for PIK3CA - only partly enters the CNS. In 2018 patients were not screened for PIK3CA mutations. Dana Farber report likely enhanced future results with chemo combo. Come alone way in 8 years, with pAX known to prep cancer, in chemo combination, for strongly enhanced Keytruda immunotherapy cancer destruction.
1
ocellated
$KZIA Is it fair to say that the second set of three patients results were not as good as the first 3? Also on Oct 20 CNBC featured a Microcap Minute on Kazia - "With approximately $80 million in available funding, Kazia is expanding its research to other cancers. Dr. Friend indicated that the next 12 to 18 months will be "transformational" as these programs move further into clinical studies and data emerges." The CEO had previously stated that he would try to close the gap between the valuation of Kazia and Celcuity in 2026. Was he just saying this to mollify the retail investors, or are they actually going to let this run?
1
santabarbarabob
$KZIA Anyone know how many outstanding shares there would be if all the warrants are exercised?
ocellated
$KZIA from the Kazia stockholders meeting Mar 25, 2026 - beginning at the 19:59 mark: “…The question reads “There have been some multi-billion dollar recent corporate activity in the PI3K class of drug. Kazia has a market cap of around 100 million. Any comments with regard to this... “… we’re super excited to be in the space and with, again, more eyes on the stock with a very strong and strategic plans in place with new banks, new analysts, research coverage, et cetera. We do believe we will be closing that gap in 2026 and beyond….”
scottpetet
$KZIA a company that only does licensing long shot compounds is recognized as drug discovery company of the year?
LabMan
$KZIA It is a sad and distressing indictment of this company,( that we all part own ) - plant based compounds are now being extensively tested, as PI3k repair treatment for Parkinson's Disease. That is what it has come down to, because of management decision not to embrace ACTUAL paxalisib research for Parkinson's Disease treatment. Research it further for yourself. We are seeing here, I am afraid - a very bad situation. Contact the company, and suggest basic, logical, common sense, should prevail here - in a low cost, high reward situation for investors ( & PD patients).

Advertisement|Remove ads.